Dr. Ryan Relich is an American Board of Medical Microbiology-certified medical microbiologist who is passionately interested in all facets of diagnostic microbiology and laboratory medicine, especially laboratory directorship, infectious disease epidemiology and pathology, new diagnostic test development and evaluation, pathogen discovery, and viral ecology. In his current academic position at the Indiana University School of Medicine, he is actively involved in fellow, resident, and student teaching, and research involving in vitro diagnostic product development, clinical trials, and emerging virus ecology. As an employee of Indiana University Health, Dr. Relich serves as the Medical Director of the Division of Clinical Microbiology, Medical Director of the Special Pathogens Unit Laboratory, and Associate Medical Director of the Division of Molecular Pathology. Dr. Relich also serves as Medical Director of Clinical Microbiology and Serology for Eskenazi Health. Dr. Relich is immensely interested in the ecology of emerging viruses, pandemic preparedness, development of dignostics for novel viruses, virus discovery and characterization, and establishing best practices for manipulating highly infectious clinical specimens for routine diagnostic testing. For more information on Dr. Relich's research interests, please click on the "Research" tab below.
1. Syed F, Li W, Relich RF, Russell PM, Zhang S, Zimmerman MK, Yu Q. 2021. Excessive matrix metalloproteinase-1 and hyperactivation of endothelial cells occurred in COVID-19 patients and were associated with the severity of COVID-19. J Infect Dis. Apr 22:jiab167. doi: 10.1093/infdis/jiab167.
2. Schneider JG, Relich RF, Datta D, Bond C, Goings M, Hadd D, Lei GS, Kedra J, John CC. 2021. Indentifying risk factors that distinguish symptomatic severe acute respiratory syndrome coronavirus 2 infection from common upper respiratory infections in children. Cureus. Feb 10;13(2):e13266. doi: 10.7759/cureus.13266.
3. Relich RF, Feldmann H, Haddock E. 2020. Methanol fixation, but not Giemsa staining, inactivates Ebola and Lassa viruses in peripheral blood smears made on plastic microscope slides. Am J Trop Med Hyg. Nov;103(5): 2085-2090. doi. 10.4269/ajtmh.19-0840.
4. Relich RF, Grabowski JM. 2020. Tick-Borne Viruses of North America. Clin Micrbiol Newsl. May;42(10): 79-86.
5. Leber AL, Lisby JG, Hansen G, Relich RF, Schneider UV, Granato P, Young S, Pareja J, Hannet I. 2020. Multicenter evaluation of the QIAstat-Dx respiratory panel for detection of viruses and bacteria in nasopharyngeal swab specimens. J Clin Microbiol. Apr 23;58(5):e00155-20.
6. Rieder CA, Rieder J, Sannajust S, Goode D, Geguchadze R, Relich RF, Molliver DC, King TE, Vaughn J, May M. 2019. A novel mechanism for Zika virus host-cell binding. Viruses. Nov 28;11(12):1101.
7. Relich RF, Leber A, Young S, Schutzbank T, Dunn R, Farhang J, Uphoff TS. 2019. Multicenter clinical evaluation of the automated Aries Bordetella Asay. J Clin Microbiol. Jan 30;57(2):e01471-18.
8. Relich RF, Buckner RJ, Emery CL, Davis TE. 2018. Comparison of 4 commercially available group B Streptococcus molecular assays using remnant rectal-vaginal enrichment broths. Diagn Microbiol Infect Dis. Aug;91(4):305-308.
9. Relich RF, Schmitt BH, Raposo H, Barker L, Blosser SJ, May M. 2018. Legionella indianapolisensis sp. nov, isolated from a patient with abscess. Int J Infect Dis. Apr;69:26-28.
10. Relich RF, Abbott AN. 2018. Syndromic and point-of-care molecular testing. Adv Molec Pathol. 1;97-113.